Short description
Amyl Therapeutics is a preclinical stage biotechnology company.
Description
Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β (Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases.
Last funding
Absolutely Noaccess
Sign in for full access
Total funding
$$3123123
Sign in for full access
Location
Liège, Liege, Belgium, Europe
Founded on
November 1, 2020
Non-profit?
No
Acquired?
No
Employees count
1-10
Revenue range
$1230 - 4560
Sign in for full access
Investors
Noaccess, Cannot Access, Nopepepe, Noaccess, Nopepepe, Uh Ohhhh, Blurry Noaccess, Noaccess, Noway Youcantaccess
Sign in for full access
Founders
Florent Gros, Pierre Vandepapelière